Seattle Genetics traded at $138.00 this Friday February 3rd, decreasing $1.43 or 1.03 percent since the previous trading session. Looking back, over the last four weeks, Seattle Genetics lost 2.30 percent. Over the last 12 months, its price rose by 0.05 percent. Looking ahead, we forecast Seattle Genetics to be priced at 133.47 by the end of this quarter and at 120.77 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
138.00
Daily Change
-1.03%
Yearly
0.05%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Regeneron Pharmaceuticals 783.13 31.93 4.25% 25.71%
Seattle Genetics 138.00 -1.43 -1.03% 0.05%
Xencor 36.49 1.35 3.84% 14.03%
Teva Pharmaceutical Industries Ltd 3,678.00 73.00 2.03% 35.27%
Sarepta Therapeutics 119.00 -1.25 -1.04% 62.77%
Spectrum Pharmaceuticals 0.81 0.004 0.52% 24.44%
Sanofi 85.02 -1.75 -2.02% -5.84%
Nektar Therapeutics 3.09 0.09 3.00% -70.46%
Insmed 21.59 -0.14 -0.64% -2.00%
Incyte Corp 83.61 -0.88 -1.04% 15.02%
Exelixis 17.55 -0.06 -0.34% -6.60%
Clovis Oncology 0.11 -0.004 -3.42% -93.72%
Celldex Therapeutics 46.09 1.11 2.47% 50.13%
Agios Pharmaceuticals 30.20 0.02 0.07% 5.08%
Acadia Pharmaceuticals 19.83 -0.08 -0.40% -15.97%
AbbVie 145.20 0.36 0.25% 3.24%
Vertex Pharmaceuticals 301.02 -2.76 -0.91% 24.41%
Pfizer 44.06 -0.28 -0.63% -16.87%
Puma Biotechnology 4.46 0.09 2.06% 84.30%
Novartis 79.63 1.37 1.75% -0.26%
Mirati Therapeutics 52.57 -1.69 -3.11% -56.16%
Moderna Inc 173.25 -3.10 -1.76% 6.28%
Merck & Co 102.94 -0.52 -0.50% 31.03%
MacroGenics 5.59 -0.33 -5.57% -51.64%
Eli Lilly 339.08 8.38 2.53% 39.96%
Karyopharm Therapeutics 3.40 -0.11 -3.13% -65.09%
Immunogen 4.66 -0.26 -5.28% -12.41%
GlaxoSmithKline 1,434.20 6.80 0.48% -12.28%
Gilead Sciences 84.50 3.11 3.82% 32.24%
Genmab 2,662.00 58.00 2.23% 18.26%
Esperion Therapeutics 5.90 -0.02 -0.34% 65.27%
BioMarin Pharmaceutical 112.20 -0.64 -0.57% 26.59%
Bluebird Bio 6.65 0.02 0.30% -2.35%
Biogen 283.63 -3.89 -1.35% 28.03%
Bayer 56.62 -0.18 -0.32% 7.60%
Amgen 245.17 -1.36 -0.55% 10.38%
Daiichi Sankyo 4,061.00 21.00 0.52% 75.80%
Eisai 7,869.00 -66.00 -0.83% 36.69%
Astellas Pharma 1,889.50 -10.50 -0.55% -5.50%
Takeda 4,171.00 117.00 2.89% 23.26%
Glaxosmithkline 34.83 -0.30 -0.85% -22.25%
Bristol-Myers Squibb 74.45 1.68 2.31% 14.56%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%
USNDX 12573 -229.78 -1.79% -13.71%

Seattle Genetics
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.